Celltrion Introduces Avtozma IV (Biosimilar, Actemra) in the US

Shots:Celltrion has launched Avtozma IV, a biosimilar to Actemra (tocilizumab) for all the approved indications of the reference product in the USIn Jan 2025, the FDA approved Avtozma based on a global P-III trial showing comparable efficacy, PK, safety & immunogenicity vs reference tocilizumab, followed by an additional July 2025 FDA approval for…

ByRidhi RastogiOctober 6, 2025

NEWS

Celltrion Secures the US FDA’s Approval for Avtozma IV (Biosimilar, Actemra) to Treat Cytokine Release Syndrome

Shots:The US FDA has approved Avtozma IV, a biosimilar to Actemra (tocilizumab), for treating cytokine release syndrome in pts (≥2yrs.), covering all Actemra IV-approved indications in the US; expected to be available in the US by Aug 31, 2025In Jan 2025, the US FDA approved Avtozma IV to treat rheumatoid arthritis (RA), giant…

ByRidhi RastogiAugust 8, 2025

VIEWPOINTS

Establishing Safe Treatment: Dr. Robert Rifikin from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots: There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United States Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…

BySaurabh ChaubeyAugust 5, 2024

Celltrion Introduces Avtozma IV (Biosimilar, Actemra) in the US

Celltrion Secures the US FDA’s Approval for Avtozma IV (Biosimilar, Actemra) to Treat Cytokine Release Syndrome

Establishing Safe Treatment: Dr. Robert Rifikin from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Contact US

OUR INFORMATION

FOLLOW US